Is there a role for stem cell therapy in erectile dysfunction secondary to cavernous nerve injury? Network meta-analysis from animal studies and human trials
Wani, M.M., Rai, B.P., Webb, W.R. and Madaan, S. 2022. Is there a role for stem cell therapy in erectile dysfunction secondary to cavernous nerve injury? Network meta-analysis from animal studies and human trials. Therapeutic Advances in Urology. 14 (1-21). https://doi.org/10.1177/17562872221086999
|Authors||Wani, M.M., Rai, B.P., Webb, W.R. and Madaan, S.|
Introduction: We carried out systematic review and network meta-analysis to investigate the role of stem cell therapy (SCT) in the management of erectile dysfunction (ED) secondary to cavernous nerve injury in rats and post-radical prostatectomy (RP) in humans.
Patients and Methods: The protocol was registered with PROSPERO database. We searched studies analyzing the efficacy of SCT for ED due to bilateral cavernous nerve injury (BCNI) in rats using Healthcare Databases Advanced Search (HDAS) Export software (MEDLINE,EMBASE, Scopus) from inception to September 2020. The outcome measurements, for 29 animal studies, were intracavernosal pressure (ICP), ICP/MAP (mean arterial pressure) ratio, and histological/molecular changes. All three available human trials evaluating SCT in post-RP ED were assessed for International Index for Erectile Function (IIEF) Score and Erection Hardness Score (EHS).
Results: For ICP measurement, animal studies were divided into adipose-derived stem cells
Conclusion: Our results confirm that SCT does improve the erectile function in rats having cavernous nerve injury. Similarly, early human results have shown promising results.
|Keywords||Stem cells; Erectile dysfunction|
|Journal||Therapeutic Advances in Urology|
|Journal citation||14 (1-21)|
|Digital Object Identifier (DOI)||https://doi.org/10.1177/17562872221086999|
|29 Mar 2022|
|Publication process dates|
|Accepted||07 Mar 2022|
|Deposited||06 Apr 2022|
File Access Level
0views this month
0downloads this month